JP2021504478A - 生殖管感染症に対する併用療法と予防 - Google Patents

生殖管感染症に対する併用療法と予防 Download PDF

Info

Publication number
JP2021504478A
JP2021504478A JP2020546303A JP2020546303A JP2021504478A JP 2021504478 A JP2021504478 A JP 2021504478A JP 2020546303 A JP2020546303 A JP 2020546303A JP 2020546303 A JP2020546303 A JP 2020546303A JP 2021504478 A JP2021504478 A JP 2021504478A
Authority
JP
Japan
Prior art keywords
omv
mice
infection
gonococcal
microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020546303A
Other languages
English (en)
Japanese (ja)
Inventor
ラッセル，マイケル，ダブリュー．
リュー，インリュー
エギルメズ，ネジャット，ケイ．
Original Assignee
ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク
ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/824,700 external-priority patent/US20180071379A1/en
Priority claimed from US16/138,526 external-priority patent/US20190008941A1/en
Application filed by ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク, ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク filed Critical ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク
Publication of JP2021504478A publication Critical patent/JP2021504478A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2020546303A 2017-11-28 2018-11-27 生殖管感染症に対する併用療法と予防 Pending JP2021504478A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15/824,700 US20180071379A1 (en) 2012-05-29 2017-11-28 Combined therapy and prophylaxis for genital tract infections
US15/824,700 2017-11-28
US16/138,526 US20190008941A1 (en) 2012-05-29 2018-09-21 Combined therapy and prophylaxis for genital tract infections
US16/138,526 2018-09-21
PCT/US2018/062590 WO2019108528A1 (fr) 2017-11-28 2018-11-27 Polythérapie et prophylaxie contre des infections du tractus génital

Publications (1)

Publication Number Publication Date
JP2021504478A true JP2021504478A (ja) 2021-02-15

Family

ID=66665780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020546303A Pending JP2021504478A (ja) 2017-11-28 2018-11-27 生殖管感染症に対する併用療法と予防

Country Status (7)

Country Link
EP (1) EP3716995A4 (fr)
JP (1) JP2021504478A (fr)
CN (1) CN111698998A (fr)
AU (1) AU2018375133A1 (fr)
CA (1) CA3083741A1 (fr)
MX (1) MX2020007237A (fr)
WO (1) WO2019108528A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease
US9827319B2 (en) * 2012-05-29 2017-11-28 The Research Foundation For The State University Of New York Combined therapy and prophylaxis for genital tract infections

Also Published As

Publication number Publication date
CN111698998A (zh) 2020-09-22
CA3083741A1 (fr) 2019-06-19
EP3716995A1 (fr) 2020-10-07
AU2018375133A1 (en) 2020-06-18
EP3716995A4 (fr) 2021-08-25
WO2019108528A1 (fr) 2019-06-06
MX2020007237A (es) 2020-09-25

Similar Documents

Publication Publication Date Title
TWI320715B (en) Improved mycoplasma hyopneumoniae bacterin vaccine
US20080112974A1 (en) Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
RU2623174C2 (ru) Вакцины и композиции против streptococcus pneumoniae
US20180177867A1 (en) Adjuvant for Vaccines, Vaccine, and Immunity Induction Method
US20210261651A1 (en) Compositions and methods for treating inflammatory bowel disease
KR20160020543A (ko) 씨. 디피실에 대해서 면역화시키는 조성물 및 방법
US9119803B2 (en) Carious tooth vaccine and preparation method
US11865169B2 (en) Vaccine composition against Chlamydiaceae infections
TW201718001A (zh) 豬物種中增強之免疫反應
CA2813612A1 (fr) Methodes et compositions utilisant des anticorps anti-ligand lps destinees au traitement et a la prevention de troubles inflammatoires
JP2021504478A (ja) 生殖管感染症に対する併用療法と予防
US20190008941A1 (en) Combined therapy and prophylaxis for genital tract infections
US20180071379A1 (en) Combined therapy and prophylaxis for genital tract infections
US9827319B2 (en) Combined therapy and prophylaxis for genital tract infections
JP2023517684A (ja) ストレプトコッカス・スイス血清型９、配列型１６に対する防御のためのワクチン
KR101599281B1 (ko) 폐렴연쇄상구균 유래 막소포체를 포함하는 폐렴연쇄상구균 백신 조성물
JP2003530358A (ja) クラミジア糖脂質ワクチン
US20230190906A1 (en) Non-toxic listeriolysin o polypeptides and uses thereof
JP2003507433A (ja) 敗血症治療において治療に用いる対象としての外膜タンパク質ａ、ペプチドグリカン関連リポタンパク質およびムレインリポタンパク質
AU2007216697A1 (en) Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
EP4304606A1 (fr) Adjuvants à base de polysaccharide pour vaccins contre virus
US20080226661A1 (en) Phage Screening Assay